Menu Search
Equities

Universe Pharmaceuticals Inc

UPC:NAQ

Universe Pharmaceuticals Inc

Actions
  • Price (USD)2.40
  • Today's Change-0.10 / -4.00%
  • Shares traded9.13k
  • 1 Year change-37.50%
  • Beta--
Data delayed at least 15 minutes, as of May 24 2024 20:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Universe Pharmaceuticals Inc is a China-based holding company mainly engaged in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives (TCMD) products targeting the elderly. Through its subsidiary, the Company sells TCMD products, biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces (TCMPs), and dietary supplements manufactured by third-party pharmaceutical companies. Its TCMD products fall into two categories: chronic condition treatments as well as cold and flu medications, including Guben Yanling Pill, Shenrong Weisheng Pill, Fengshitong Medicinal Liquor, Isatis Root Granule and Qiangli Pipa Syrup. Its major customers are pharmaceutical companies, hospitals, clinics and drugstore chains. The Company mainly conducts its businesses within the Chinese market.

  • Revenue in USD (TTM)32.31m
  • Net income in USD-6.16m
  • Incorporated2019
  • Employees225.00
  • Location
    Universe Pharmaceuticals Inc265 Jingjiu AvenueJinggangshan Econ. And Tech. Dev. ZoneJI'AN 343100ChinaCHN
  • Phone+86 7 968403309
  • Websitehttp://www.universe-pharmacy.com/
More ▼

Institutional shareholders

0.04%Per cent of shares held by top holders
HolderShares% Held
UBS Securities LLCas of 31 Mar 20241.09k0.03%
Acadian Asset Management LLCas of 31 Mar 2024300.000.01%
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.